Skip to main content

Table 2 Medication usage

From: Nonsteroidal anti-inflammatory drug exposure and the risk of microscopic colitis

Medication

Total (%)

New MC (%)

MC Registry (%)

p-vala

MC (%)

No MC (%)

p-valb

Any Dose Aspirin

42 (21.21)

6 (28.57)

19 (32.20)

0.77

25 (31.25)

17 (14.41)

 < 0.01

Other NSAIDs

56 (28.28)

9 (42.86)

23 (39.65)

0.80

32 (40.51)

24 (20.34)

 < 0.01

Any Aspirin or NSAIDs

77 (38.89)

11 (52.38)

32 (54.24)

0.88

43 (53.75)

34 (28.81)

 < 0.01

PPIs

48 (24.24)

4 (19.05)

14 (23.73)

0.66

18 (22.50)

30 (25.42)

0.64

H2RAs

10 (5.05)

1 (4.76)

5 (8.47)

0.59

6 (7.50)

4 (3.39)

0.20

SSRIs

57 (28.79)

6 (28.57)

21 (35.59)

0.56

27 (33.75)

30 (25.42)

0.20

Statins

54 (27.27)

5 (23.81)

17 (28.81)

0.66

22 (27.50)

32 (27.12)

0.95

ACE-Is

18 (9.09)

1 (4.76)

2 (3.38)

1.00

3 (3.75)

15 (12.71)

0.03

ARBs

16 (8.08)

2 (15.38)

3 (5.08)

0.21

5 (6.94)

11 (11.11)

0.36

  1. Medication use was compared between sources of microscopic colitis (MC) patients (p-vala), and between MC and no MC (p-valb) utilizing univariate statistics. NSAIDs: non-steroidal anti-inflammatory drugs, PPIs: proton pump inhibitors, H2RAs: histamine-2 receptor antagonists, SSRIs: selective serotonin reuptake inhibitors, ACE-Is: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers